Oestrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer
Open Access
- 1 February 2000
- journal article
- review article
- Published by Springer Nature in British Journal of Cancer
- Vol. 82 (3) , 501-513
- https://doi.org/10.1054/bjoc.1999.0954
Abstract
No abstract availableKeywords
This publication has 96 references indexed in Scilit:
- Overexpressions of c-fos/jun mRNA and their oncoproteins (Fos/Jun) in the mouse uterus treated with three natural estrogensCancer Letters, 1995
- Oncogene Protein Co-Expression Value of Ha-ras, c-myc, c-fos, and p53 as Prognostic Discriminants for Breast CarcinomaAnnals of Surgery, 1995
- Effect of endocrine therapy on growth of T61 human breast cancer xenografts is directly correlated to a specific down-regulation of insulin-like growth factor II (IGF-II)European Journal Of Cancer, 1993
- Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivityEuropean Journal Of Cancer, 1993
- Type I IGF receptor and acquired tamoxifen resistance in oestrogen-responsive human breast cancer cellsEuropean Journal Of Cancer, 1993
- The role of four oestrogen-responsive genes, pLIV1, pS2, pSYD3 and pSYD8, in predicting responsiveness to endocrine therapy in primary breast cancerEuropean Journal Of Cancer, 1993
- C-fos, C-jun and C-myc expressions are not growth rate limiting for the human MCF-7 breast cancer cellsBiochemical and Biophysical Research Communications, 1992
- Transforming growth factor beta1 in ductal carcinoma in situ and invasive carcinomas of the breastEuropean Journal Of Cancer, 1992
- Heterogeneity of oestrogen receptor expression in normal and malignant breast tissueEuropean Journal Of Cancer, 1992
- Transforming growth factor β1 is implicated in the failure of tamoxifen therapy in human breast cancerBritish Journal of Cancer, 1991